Clinical Trial Update: Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

This phase 2 trial compared continuing docetaxel versus switching to cabazitaxel after a minor PSA response in metastatic castration-resistant prostate cancer; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Jevtana (cabazitaxel)

Snippet

Sponsor: Sanofi | Conditions: Prostatic Neoplasms | Phase 2 | Status: COMPLETED